Cyclic Amide Sigma Receptor Ligands for Schizophrenia Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for schizophrenia, particularly for negative symptoms, have shown limited efficacy and are often associated with significant side effects, necessitating the development of new medicaments and methods that target sigma receptor binding sites to improve therapeutic outcomes.

Innovation Solution

Compounds with high affinity for sigma 2 receptors, such as those described in formulas I and II, are developed to treat schizophrenia and its symptoms by preferentially binding to these sites, reducing the impact of positive symptoms while effectively addressing negative symptoms without significant side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for schizophrenia are used, then positive symptoms may be addressed, but negative symptoms show limited benefit and significant side effects occur

Engineering Contradiction:

Improvetreatment efficacy for negative symptomsVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent segments the treatment approach by targeting specific sigma receptor subtypes (sigma-1 and sigma-2) rather than using broad-spectrum antipsychotics. This selective targeting allows differential treatment of positive and negative symptoms while minimizing off-target side effects associated with traditional dopamine antagonists

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent introduces sigma receptor ligands as intermediary compounds that mediate treatment effects through a novel mechanism. These compounds act as intermediaries between the administered drug and the therapeutic outcome, engaging sigma receptors to produce antipsychotic effects with improved side effect profiles compared to direct dopamine pathway modulation

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If traditional antipsychotic drugs are used, then positive symptoms may be reduced, but negative symptoms remain untreated and side effects increase

Engineering Contradiction:

Improveside effectsVSAvoidtreatment efficacy for negative symptoms

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent changes the pharmacological parameters by shifting from dopamine D2 receptor antagonism to sigma receptor ligand binding. This parameter change in the mechanism of action enables treatment of negative symptoms through sigma-1 and sigma-2 receptor engagement, producing therapeutic effects with reduced side effect burden

Inventive Principle:

Principle #35Parameter changes

3Reliability

If new medicaments targeting sigma receptor binding sites are developed, then treatment efficacy for negative symptoms improves, but development complexity increases

Engineering Contradiction:

Improvetreatment efficacy for negative symptomsVSAvoidmedicament development complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent achieves multi-functionality by designing sigma receptor ligands that can simultaneously address multiple symptom domains (positive and negative symptoms) through a single mechanism of action. This universal approach consolidates treatment into one drug class with dual therapeutic capabilities, reducing the need for multiple specialized medications

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS9732059B2Methods of use of cyclic amide derivatives to treat schizophrenia

Publication Date: 2017.08.15 MINERVA NEUROSCIENCES INC

AI summary

Disclosed herein are compositions and methods for treating schizophrenia and symptoms of schizophrenia, including negative symptoms of schizophrenia.